hd 1

PRO-HD1, a PROTAC (proteolysis-targeting chimera) HDAC6 degrader, effectively degrades HDAC6 in A549 cells and inhibits Jurkat cell proliferation with an IC50 of 5.8 µM [1].

MC1568 is a specific HDAC inhibitor for maize HD1-A (IC50: 100 nM, in a cell-free assay). It is 34-fold more selective for HD1-A than HD1-B.

Givinostat hydrochloride monohydrate (ITF2357) is an HDAC inhibitor.

Givinostat hydrochloride (ITF2357 hydrochloride) is an inhibitor of HDAC with IC50 of 198 and 157 nM for HDAC1 and HDAC3, respectively. Givinostat hydrochloride exhibits anti-inflammatory, anti-angiogenic, and antineoplastic activities.

μ-TRTX-Hd1a, a spider venom-derived compound, selectively inhibits the human NaV 1.7 channel by functioning as a gating modifier, interacting with the S3b-S4 paddle motif within domain II of the channel [1].

DO-264 is an inhibitor of autohydrolase structural domain 12 (ABHD12) (IC50: 11 nM) and an inhibitor of cellular LysoPS degradation that enhances LPS-induced phagocytosis.

TH7127 is a selective inhibitor of the sterile alpha motif and histidine-aspartate domain-containing protein-1 (SAMHD1), inhibits hydrolysis of ara-CTP and Cl-F-ara-ATP, and inhibits the enzymatic activity of SAMHD1 on dGTP, Cl-F-ara-ATP, and ara-CTP.

PHD-1-IN-1 is a potent inhibitor of hypoxia-inducible factor prolylhydroxylase domain-1 (PHD-1) enzyme(IC50 = 0.034 μM).

CHD-1 is a hypoxia-activated antitumor prodrug. It disrupts the mitochondrial morphology and membrane potential of hypoxic tumor cells, leading to excessive mitophagy and inducing apoptosis. In vitro, CHD-1 inhibits the growth of hypoxic tumor cells, while in vivo, it suppresses the growth of HeLa xenograft tumors.

Molidustat (BAY 85-3934)(BAY-85-3934), an inhibitor of hypoxia-inducible factor (HIF) prolyl hydroxylase (PH), stimulates erythropoietin (EPO) production and the formation of red blood cells.

UTA1inh-D1 is a novel inhibitor of kidney urea transporter UT-A1 .

JNJ-42041935 (HIF-PHD Inhibitor II) is a potent (pKi = 7.3-7.9), 2-oxoglutarate competitive, reversible, and selective inhibitor of PHD enzymes.

Givinostat (ITF-2357) is an HDAC inhibitor with IC50 values of 198 nM for HDAC1 and 157 nM for HDAC3.

MK-8617 is an orally available HIF PHD1 3 pan-inhibitor, inhibiting PHD1/2/3 (IC50: 1.0/1.0/14 nM).

TP-0463518 is a highly potent HIF prolyl hydroxylase (PHD) inhibitor (IC50s: 13 nM and 18 nM for human and rat PHD2, respectively).

CHD1Li 6.11 is a potent inhibitor of oncogenic CHD1L, acting on the cat-CHD1L recombinant protein (IC50: 3.3 μM). CHD1Li 6.11 is an orally active antitumour agent that significantly reduces the tumour volume of CRC xenografts generated from isolated quasi-mesenchymal cells (M phenotype) with enhanced tumourigenic properties. These cells have enhanced tumourigenic properties.

Cephalosporin C zinc salt was a potent inhibitor of SAMHD1 (IC50 : 1.1 ± 0.1 µM), and this inhibition was largely attributable to the presence of zinc.

PhD1, an antimicrobial peptide originating from monkey leukocytes, exhibits efficacy against various bacteria and the fungus Candida albicans [1].

HDL-16 is a highly effective P2Y14R antagonist with anti-colitis effects, targeting P2Y14R in intestinal epithelial cells to alleviate ulcerative colitis.

ML226 is a α/β hydrolase domain-containing protein 11 (ABHD11) inhibitor that inhibits ABHD11 in vitro and in situ.

AA38-3 (1-Piperidinecarboxylic acid, 4-nitrophenyl ester) inhibites three SHs (ABHD6, ABHD11, and FAAH)

Fmoc-Leu-OH-d10 is a deuterated compound of Fmoc-Leu-OH. Fmoc-Leu-OH has a CAS number of 35661-60-0. NPC 15199 is an anti-inflammatory agent.

C16-pHD108 is a pH-responsive nanopore-forming peptide that acts as a macromolecular delivery vector through nanoperforation of the endosomal membrane. C16-pHD108 shows potential for research applications in cancer and neurodegenerative diseases.

5-Hydroxy-1-methylhydantoin (HD-003) is an antioxidant potentially for the treatment of renal failure. A creatinine metabolite, 5-Hydroxy-1-methylhydantoin , a hydroxyl radical scavenger, has previously been shown to confer renoprotection by inhibiting the progression of chronic kidney disease in rats. 5-Hydroxy-1-methylhydantoin is a novel anti-oxidant drug completely suppressed the expression of B2-kinin receptors (B2KR) in response to high glucose (25 mM) stimulation in VSMC and was also shown to attenuate the effects of BK on VSMC remodeling. 5-Hydroxy-1-methylhydantoin inhibited the BK-induced increase in MAPK phosphorylation and attenuated the increase in connective tissue growth factor (CTGF) protein levels in VSMC. These findings suggest that 5-Hydroxy-1-methylhydantoin may confer vascular protection against high glucose concentrations and BK-stimulation to ameliorate vascular injury and remodeling through its anti-oxidant properties.